Valentina Svicher

Qualifica
ASSOCIATO CONFERMATO
Fonte dei dati: Archivio della Ricerca http://art.torvergata.it
  1. Foroghi Biland, L., Ferrari, L., Malagnino, V., Teti, E., Cerva, C., Gentile, A., et al. (2019). Hepatitis B virus reactivation sustained by a hepatitis B virus surface antigen immune-escape mutant isolate in a patient who was hepatitis B core antibody positive during treatment with sofosbuvir and velpatasvir for hepatitis C virus infection: A case report. JOURNAL OF MEDICAL CASE REPORTS, 13(1), 299. Dettagli
  2. Malagnino, V., Cerva, C., Maffongelli, G., Teti, E., Foroghi Biland, L., Cesta, N., et al. (2019). HBcAb seropositivity is correlated with poor HIV viremia control in an Italian cohort of HIV/HBV-coinfected patients on first-line therapy. SCIENTIFIC REPORTS, 9(1), 11942. Dettagli
  3. Salpini, R., Battisti, A., Colagrossi, L., Di Carlo, D., Fabeni, L., Piermatteo, L., et al. (2019). A snapshot of virological presentation and outcome of immunosuppression-driven HBV reactivation from real clinical practice: Evidence of a relevant risk of death and evolution from silent to chronic infection. JOURNAL OF VIRAL HEPATITIS, 26(7), 846-855. Dettagli
  4. Alteri, C., Scutari, R., Stingone, C., Maffongelli, G., Brugneti, M., Falasca, F., et al. (2019). Quantification of HIV-DNA and residual viremia in patients starting ART by droplet digital PCR: Their dynamic decay and correlations with immunological parameters and virological success. JOURNAL OF CLINICAL VIROLOGY, 117, 61-67. Dettagli
  5. Ciardi, M.r., Iannetta, M., Zingaropoli, M.a., Salpini, R., Aragri, M., Annecca, R., et al. (2019). Reactivation of Hepatitis B Virus With Immune-Escape Mutations After Ocrelizumab Treatment for Multiple Sclerosis. OPEN FORUM INFECTIOUS DISEASES, 6(1), ofy356. Dettagli
  6. Alteri, C., Scutari, R., Bertoli, A., Armenia, D., Gori, C., Fabbri, G., et al. (2019). Integrase strand transfer inhibitor-based regimen is related with a limited HIV-1 V3 loop evolution in clinical practice. VIRUS GENES. Dettagli
  7. Grande, F., Occhiuzzi, M.a., Rizzuti, B., Ioele, G., De Luca, M., Tucci, P., et al. (2019). CCR5/CXCR4 dual antagonism for the improvement of HIV infection therapy. MOLECULES, 24(3), 550. Dettagli
  8. Salpini, R., Surdo, M., Cortese, M., Palumbo, G., Carioti, L., Cappiello, G., et al. (2019). The novel HBx mutation F30V correlates with hepatocellular carcinoma in vivo, reduces hepatitis B virus replicative efficiency and enhances anti-apoptotic activity of HBx N terminus in vitro. CLINICAL MICROBIOLOGY AND INFECTION, 25(7). Dettagli
  9. Salpini, R., Surdo, M., Cortese, M.f., Palumbo, G.a., Carioti, L., Cappiello, G., et al. (2019). The novel HBx mutation F30V correlates with hepatocellular carcinoma in vivo, reduces hepatitis B virus replicative efficiency and enhances anti-apoptotic activity of HBx N terminus in vitro. CLINICAL MICROBIOLOGY AND INFECTION, 25(7). Dettagli
  10. Alteri, C., Fabeni, L., Scutari, R., Berno, G., Di Carlo, D., Gori, C., et al. (2018). Genetic divergence of HIV-1 B subtype in Italy over the years 2003–2016 and impact on CTL escape prevalence. SCIENTIFIC REPORTS, 8(1), 15739. Dettagli
  11. Colagrossi, L., Salpini, R., Scutari, R., Carioti, L., Battisti, A., Piermatteo, L., et al. (2018). HDV can constrain HBV genetic evolution in hbsag: Implications for the identification of innovative pharmacological targets. VIRUSES, 10(7), 363. Dettagli
  12. Colagrossi, L., Hermans, L.e., Salpini, R., Di Carlo, D., Pas, S.d., Alvarez, M., et al. (2018). Immune-escape mutations and stop-codons in HBsAg develop in a large proportion of patients with chronic HBV infection exposed to anti-HBV drugs in Europe. BMC INFECTIOUS DISEASES, 18(1), 251. Dettagli
  13. Malagnino, V., Salpini, R., Maffongelli, G., Battisti, A., Fabeni, L., Piermatteo, L., et al. (2018). High rates of chronic HBV genotype E infection in a group of migrants in Italy from West Africa: Virological characteristics associated with poor immune clearance. PLOS ONE, 13(3), e0195045. Dettagli
  14. Scutari, R., Faieta, M., D'Arrigo, R., Fabeni, L., Mussini, C., Cossarizza, A., et al. (2018). The degree of HIV-1 amino acid variability is strictly related to different disease progression rates. VIRUS GENES, 54(4), 493-501. Dettagli
  15. Svicher, V., Marchetti, G., Ammassari, A., Ceccherini-silberstein, F., & Sarmati, L. (2017). Novelties in Evaluation and Monitoring of Human Immunodeficiency Virus-1 Infection: Is Standard Virological Suppression Enough for Measuring Antiretroviral Treatment Success?. AIDS REVIEWS, 19(3). Dettagli
  16. Cerva, C., Maffongelli, G., Svicher, V., Salpini, R., Colagrossi, L., Battisti, A., et al. (2017). Hepatitis B reactivation characterized by HBsAg negativity and anti-HbsAg antibodies persistence in haematopoietic stem cell transplanted patient after lamivudine withdrawal. BMC INFECTIOUS DISEASES, 17(1), 566. Dettagli
  17. Scutari, R., Alteri, C., Perno, C.f., Svicher, V., & Aquaro, S. (2017). The role of HIV infection in neurologic injury. BRAIN SCIENCES, 7(4), 38. Dettagli
  18. Salpini, R., Surdo, M., Warner, N., Cortese, M.f., Colledge, D., Soppe, S., et al. (2017). Novel HBsAg mutations correlate with hepatocellular carcinoma, hamper HBsAg secretion and promote cell proliferation in vitro. ONCOTARGET. Dettagli
  19. Di Maio, V.c., Cento, V., Lenci, I., Aragri, M., Rossi, P., Barbaliscia, S., et al. (2017). Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies. LIVER INTERNATIONAL, 37(4), 514-528. Dettagli
  20. Borrajo, A., Ranazzi, A., Pollicita, M., Bruno, R., Modesti, A., Alteri, C., et al. (2017). Effects of amprenavir on HIV-1 maturation, production and infectivity following drug withdrawal in chronically-infected monocytes/macrophages. VIRUSES, 9(10), 277. Dettagli
  21. Sarmati, L., Andreoni, M., Antonelli, G., Arcese, W., Bruno, R., Coppola, N., et al. (2017). Recommendations for screening, monitoring, prevention, prophylaxis and therapy of hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation—a position paper. CLINICAL MICROBIOLOGY AND INFECTION, 23(12), 935-940. Dettagli
  22. Alteri, C., Surdo, M., Di Maio, V., Di Santo, F., Costa, G., Parrotta, L., et al. (2016). The HIV-1 reverse transcriptase polymorphism A98S improves the response to tenofovir disoproxil fumarate + emtricitabine-containing HAART both in vivo and in vitro. JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 7, 1-7. Dettagli
  23. Cerva, C., Colagrossi, L., Maffongelli, G., Salpini, R., Di Carlo, D., Malagnino, V., et al. (2016). Persistent risk of HBV reactivation despite extensive lamivudine prophylaxis in haematopoietic stem cell transplant recipients who are anti-HBc-positive or HBV-negative recipients with an anti-HBc-positive donor. CLINICAL MICROBIOLOGY AND INFECTION. Dettagli
  24. Nozza, S., Pignataro, A.r., Galli, L., Svicher, V., Alteri, C., Boeri, E., et al. (2016). 48 week outcomes of maraviroc-containing regimens following the genotypic or Trofile assay in HIV-1 failing subjects: the OSCAR Study. NEW MICROBIOLOGICA, 39(3), 192-196. Dettagli
  25. Lenci, I., Baiocchi, L., Tariciotti, L., Di Paolo, D., Milana, M., Santopaolo, F., et al. (2016). Complete hbv prophylaxis withdrawal in HBsAg-positive liver transplant recipients after long-term minimal immunosuppression. LIVER TRANSPLANTATION. Dettagli
  26. Aragri, M., Alteri, C., Battisti, A., Di Carlo, D., Minichini, C., Sagnelli, C., et al. (2016). Multiple Hepatitis B Virus (HBV) Quasispecies and Immune-Escape Mutations Are Present in HBV Surface Antigen and Reverse Transcriptase of Patients with Acute Hepatitis B. THE JOURNAL OF INFECTIOUS DISEASES, 213(12), 1897-1905. Dettagli
  27. Hermans, L.e., Svicher, V., Pas, S.d., Salpini, R., Alvarez, M., Ben Ari, Z., et al. (2016). Combined analysis of the prevalence of drug-resistant Hepatitis B virus in antiviral therapy-experienced patients in Europe (CAPRE). THE JOURNAL OF INFECTIOUS DISEASES, 213(1), 39-48. Dettagli
  28. Maffongelli, G., Alterib, C., Gentilotti, E., Bertoli, A., Ricciardi, A., Malagnino, V., et al. (2016). Impact of HIV-1 tropism on the emergence of non-AIDS events in HIV-infected patients receiving fully suppressive antiretroviral therapy. AIDS. Dettagli
  29. Fabeni, L., Berno, G., Svicher, V., Ceccherini-Silberstein, F., Gori, C., Bertoli, A., et al. (2015). Genotypic tropism testing in HIV-1 proviral DNA can provide useful information at low-level viremia. JOURNAL OF CLINICAL MICROBIOLOGY, 53(9), 2935-2941. Dettagli
  30. Alteri, C., Surdo, M., Bellocchi, M.c., Saccomandi, P., Continenza, F., Armenia, D., et al. (2015). Incomplete APOBEC3G/F neutralization by HIV-1 Vif mutants facilitates the genetic evolution from CCR5 to CXCR4 usage. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 59(8), 4870-4881. Dettagli
  31. Surdo, M., Alteri, C., Puertas, M.C., Saccomandi, P., Parrotta, L., Swenson, L., et al. (2015). Effect of maraviroc on non-R5 tropic HIV-1: Refined analysis of subjects from the phase IIb study A4001029. CLINICAL MICROBIOLOGY AND INFECTION, 21(1), 103.e1-103.e6. Dettagli
  32. Armenia, D., Fabeni, L., Alteri, C., Di Pinto, D., Di Carlo, D., Bertoli, A., et al. (2015). HIV-1 integrase genotyping is reliable and reproducible for routine clinical detection of integrase resistance mutations even in patients with low-level viraemia. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 70(6), 1865-1873. Dettagli
  33. Di Maio, V., Cento, V., Di Paolo, D., Aragri, M., De Leonardis, F., Tontodonati, M., et al. (2015). HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. Dettagli
  34. Pollicita, M., Alteri, C., Bellocchi, M.C., Armenia, D., Carioti, L., Salpini, R., et al. (2015). A recent epidemiological cluster of acute hepatitis B genotype F1b infection in a restricted geographical area of Italy. CLINICAL MICROBIOLOGY AND INFECTION, 21(12), 1124.e1-1124.e4. Dettagli
  35. Mirabelli, C., Surdo, M., Van Hemert, F., Lian, Z., Salpini, R., Cento, V., et al. (2014). Specific mutations in the C-terminus domain of HBV surface antigen significantly correlate with low level of serum HBV-DNA in patients with chronic HBV infection. JOURNAL OF INFECTION. Dettagli
  36. Salpini, R., Colagrossi, L., Bellocchi, M., Surdo, M., Becker, C., Alteri, C., et al. (2014). Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression. HEPATOLOGY, 61(3), 823-833. Dettagli
  37. Matteucci, C., Sorrentino, R., Bellis, L., Ettorre, G., Svicher, V., Santoro, R., et al. (2014). Detection of high levels of Survivin-immunoglobulin M immune complex in sera from hepatitis C virus infected patients with cirrhosis. HEPATOLOGY RESEARCH, 44(9), 1008-1018. Dettagli
  38. Armenia, D., Soulie, C., Di Carlo, D., Fabeni, L., Gori, C., Forbici, F., et al. (2014). A very low geno2pheno false positive rate is associated with poor viro-immunological response in drug-naïve patients starting a first-line HAART. PLOS ONE, 9(8). Dettagli
  39. Svicher, V., Ceccherini-Silberstein, F., Antinori, A., Aquaro, S., & Perno, C. (2014). Understanding HIV compartments and reservoirs. CURRENT HIV/AIDS REPORTS, 11(2), 186-194. Dettagli
  40. Pollicita, M., Surdo, M., di Santo, F., Cortese, M.f., Fabeni, L., Fedele, V., et al. (2014). Comparative replication capacity of raltegravir-resistant strains and antiviral activity of the new-generation integrase inhibitor dolutegravir in human primary macrophages and lymphocytes. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 69(9), 2412-2419. Dettagli
  41. Svicher, V., Alteri, C., Santoro, M., Ceccherini-Silberstein, F., Marcelin, A., Calvez, V., et al. (2014). The multifactorial pathways towards resistance to the cytosine analogues emtricitabine and lamivudine: Evidences from literature. JOURNAL OF INFECTION. Dettagli
  42. Svicher, V., Alteri, C., Montano, M., Nori, A., D'Arrigo, R., Andreoni, M., et al. (2014). Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group. INFECTION, 42(1), 61-71. Dettagli
  43. Monforte, A., Svicher, V., Nozza, S., Lazzarin, A., Marchetti, G., & Perno, C. (2014). Highlights on HIV eradication in 2013. AIDS, 28(1), 1-7. Dettagli
  44. Surdo, M., Balestra, E., Saccomandi, P., Di Santo, F., Montano, M., Di Carlo, D., et al. (2013). Inhibition of dual/mixed tropic HIV-1 isolates by CCR5-inhibitors in primary lymphocytes and macrophages. PLOS ONE, 8(7), e68076-e68076. Dettagli
  45. Cento, V., Van Hemert, F., Neumann Fraune, M., Mirabelli, C., Di Maio, V., Salpini, R., et al. (2013). Anti-HBV treatment induces novel reverse transcriptase mutations with reflective effect on HBV S antigen. JOURNAL OF INFECTION, 67(4), 303-312. Dettagli
  46. Salpini, R., Alteri, C., Cento, V., Pollicita, M., Micheli, V., Gubertini, G., et al. (2013). Snapshot on drug-resistance rate and profiles in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice. JOURNAL OF MEDICAL VIROLOGY, 85(6), 996-1004. Dettagli
  47. Alteri, C., Artese, A., Beheydt, G., Santoro, M., Costa, G., Parrotta, L., et al. (2013). Structural modifications induced by specific HIV-1 protease-compensatory mutations have an impact on the virological response to a first-line lopinavir/ritonavir-containing regimen. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 68(10), 2205-2209. Dettagli
  48. Chen, M., Svicher, V., Artese, A., Costa, G., Alteri, C., Ortuso, F., et al. (2013). Detecting and understanding genetic and structural features in HIV-1 B subtype V3 underlying HIV-1 co-receptor usage. BIOINFORMATICS, 29(4), 451-460. Dettagli
  49. Santoro, M., Armenia, D., Alteri, C., Flandre, P., Calcagno, A., Santoro, M., et al. (2013). Impact of pre-therapy viral load on virological response to modern first-line HAART. ANTIVIRAL THERAPY, 18(7), 867-876. Dettagli
  50. Charpentier, C., Lambert-Niclot, S., Alteri, C., Storto, A., Flandre, P., Svicher, V., et al. (2013). Description of the L76V resistance protease mutation in HIV-1 B and "non-B" subtypes. PLOS ONE, 8(1), e54381-e54381. Dettagli
  51. Salpini, R., Alteri, C., Cento, V., Pollicita, M., Micheli, V., Gubertini, G., et al. (2013). Snapshot on drug-resistance rate and profiles in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice. JOURNAL OF MEDICAL VIROLOGY, 85(6), 996-1004. Dettagli
  52. Svicher, V., Cento, V., Rozera, G., Abbate, I., Santoro, M., Armenia, D., et al. (2013). The genotypic false positive rate determined by V3 population sequencing can predict the burden of HIV-1 CXCR4-using species detected by pyrosequencing. PLOS ONE, 8(1). Dettagli
  53. Cento, V., Mirabelli, C., Dimonte, S., Salpini, R., Han, Y., Trimoulet, P., et al. (2012). Overlapping structure of HBV genome and immune selection pressure are critical forces modulating HBV evolution. JOURNAL OF GENERAL VIROLOGY. Dettagli
  54. Santoro, M., Armenia, D., Fabeni, L., Santoro, M., Gori, C., Forbici, F., et al. (2012). The lowest X4 Geno2Pheno false-positive rate is associated with greater CD4 depletion in HIV-1 infected patients. CLINICAL MICROBIOLOGY AND INFECTION, 18(8). Dettagli
  55. Dimonte, S., Babakir-Mina, M., Mercurio, F., Di Pinto, D., Ceccherini-Silberstein, F., Svicher, V., et al. (2012). Selected amino acid changes in HIV-1 subtype-C gp41 are associated with specific gp120(V3) signatures in the regulation of co-receptor usage. VIRUS RESEARCH. Dettagli
  56. Svicher, V., Cento, V., Bernassola, M., Neumann-Fraune, M., Van Hemert, F., Chen, M., et al. (2012). Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection. ANTIVIRAL RESEARCH, 93(1), 86-93. Dettagli
  57. Cento, V., Mirabelli, C., Salpini, R., Dimonte, S., Artese, A., Costa, G., et al. (2012). HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors. PLOS ONE, 7(7), e39652-e39652. Dettagli
  58. Cento, V., Van Hemert, F., Di Maio, V., Salpini, R., Mirabelli, C., Bertoli, A., et al. (2012). Novel reverse transcriptase mutations specifically associated with selected anti-Hbv treatment can induce alterations and stop-codons in Hbv S antigen. In JOURNAL OF HEPATOLOGY (pp.S198-S199). Dettagli
  59. Cunyat, F., Marfil, S., Garcia, E., Svicher, V., Perez-Alvarez, N., Curriu, M., et al. (2012). The HR2 polymorphism N140I in the HIV-1 gp41 combined with the HR1 V38A mutation is associated with a less cytopathic phenotype. RETROVIROLOGY, 9(15). Dettagli
  60. Dimonte, S., Mercurio, F., Svicher, V., Perno, C., & Ceccherini-Silberstein, F. (2012). Genetic and Structural Analysis of HIV-1 Rev Responsive Element Related to V38A and T18A Enfuvirtide Resistance Mutations. INTERVIROLOGY, 55(5), 385-390. Dettagli
  61. Svicher, V., Alteri, C., Montano, M., D'Arrigo, R., Andreoni, M., Angarano, G., et al. (2012). Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA Study Group. NEW MICROBIOLOGICA, 35(1), 17-25. Dettagli
  62. Svicher, V., Mirabelli, C., Cento, V., Salpini, R., Di Maio, V., Bertoli, A., et al. (2012). Key patterns of HBX and pre-S1/S2 mutations are involved in mechanisms underlying HBV-induced hepatocellular carcinoma in vivo. Paper presented at 47th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Barcelona, SPAIN. Dettagli
  63. Alcaro, S., Alteri, C., Artese, A., Ceccherini-Silberstein, F., Costa, G., Ortuso, F., et al. (2011). Docking Analysis and Resistance Evaluation of Clinically Relevant Mutations Associated with the HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors Nevirapine, Efavirenz and Etravirine. CHEMMEDCHEM, 6(12), 2203-2213. Dettagli
  64. Ceccarelli, L., Salpini, R., Sarmati, L., Svicher, V., Bertoli, A., Sordillo, P., et al. (2011). Late hepatitis B virus reactivation after lamivudine prophylaxis interruption in an anti-HBs-positive and anti-HBc-negative patient treated with rituximab-containing therapy. JOURNAL OF INFECTION, 65(2). Dettagli
  65. Svicher, V., Cento, V., Bernassola, M., Neumann-Fraune, M., Hemert, F., Chen, M., et al. (2011). Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection. ANTIVIRAL RESEARCH, 93(1), 86-93. Dettagli
  66. Alteri, C., Santoro, M.M., Abbate, I., Rozera, G., Bruselles, A., Bartolini, B., et al. (2011). 'Sentinel' mutations in standard population sequencing can predict the presence of HIV-1 reverse transcriptase major mutations detectable only by ultra-deep pyrosequencing. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. Dettagli
  67. Alteri, C., Santoro, M.M., Abbate, I., Rozera, G., Bruselles, A., Bartolini, B., et al. (2011). 'Sentinel' mutations in standard population sequencing can predict the presence of HIV-1 reverse transcriptase major mutations detectable only by ultra-deep pyrosequencing. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. Dettagli
  68. Dimonte, S., Svicher, V., Salpini, R., Ceccherini-Silberstein, F., Perno, C.F., & Babakir-Mina, M. (2011). HIV-2 A-subtype gp125(C2-V3-C3) mutations and their association with CCR5 and CXCR4 tropism. ARCHIVES OF VIROLOGY. Dettagli
  69. Sarrecchia, C., Svicher, V., Volpi, A., Salpini, R., Ceccarelli, L., Sordillo, P., et al. (2011). Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance. INFECTION. Dettagli
  70. Dimonte, S., Mercurio, F., Svicher, V., D'Arrigo, R., Perno, C., & Ceccherini-Silberstein, F. (2011). Selected Amino Acid Mutations in HIV-1 B Subtype gp41 are Associated with Specific gp120v3 Signatures in the Regulation of Co-Receptor Usage. RETROVIROLOGY, 8(1), 33. Dettagli
  71. Callegaro, A., Svicher, V., Alteri, C., Lo Presti, A., Valenti, D., Goglio, A., et al. (2011). Epidemiological network analysis in HIV-1 B infected patients diagnosed in Italy between 2000 and 2008. INFECTION GENETICS AND EVOLUTION, 11(3), 624-632. Dettagli
  72. Svicher, V., Balestra, E., Cento, V., Sarmati, L., Dori, L., Vandenbroucke, I., et al. (2011). HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro. ANTIVIRAL RESEARCH, 90(1), 42-53. Dettagli
  73. Alcaro, S., Alteri, C., Artese, A., Ceccherini Silberstein, F., Costa, G., Ortuso, F., et al. (2011). Molecular and structural aspects of clinically relevant mutations related to the approved non-nucleoside inhibitors of HIV-1 reverse transcriptase. DRUG RESISTANCE UPDATES, 14(3), 141-149. Dettagli
  74. Lenci, I., Tisone, G., Di Paolo, D., Marcuccilli, F., Tariciotti, L., Ciotti, M., et al. (2011). Safety of complete and sustained prophylaxis withdrawal in patients liver-transplanted for HBV-related cirrhosis at low risk of HBV recurrence. JOURNAL OF HEPATOLOGY, 55(3), 587-593. Dettagli
  75. Alteri, C., Artese, A., Zang, J.M., Mercurio, F., Costa, G., Stazi, F., et al. (2011). Signature mutations in V3 and bridging sheet domain of HIV-1 gp120 are specifically associated with dual tropism and modulate the interaction with CCR5 N-terminus. Paper presented at 3th ICAR – Italian Conference on AIDS and Retroviruses, Firenze, Italia. Dettagli
  76. Ceccherini-Silberstein, F., Surdo, M., Alteri, C., Puertas, M.C., Saccomandi, P., Artese, A., et al. (2011). HIV-1 R5+ /X4- tropic viruses can be inhibited in vitro as well as in vivo by maraviroc: a refined analysis of patients enrolled in the Phase IIb study A4001029. Paper presented at International Workshop on HIV & Hepatitis virus Drug Resistance and curative strategies, Los Cabos, Mexico. Dettagli
  77. Cento, V., Mirabelli, C., Salpini, R., Han, Y., Mercurio, F., Dimonte, S., et al. (2011). Overlapping Structure of HBV genome and immune selecting pressure are the main driving forces for HBV evolution. Paper presented at 46th Annual meeting of the European Association for the study of the liver, Berlin, Germany. Dettagli
  78. Cento, V., Svicher, V., Rozera, G., Abbate, I., Santoro, M., Armenia, D., et al. (2011). The Genotypic False Positive Rate Determined by Population V3-Sequencing can Predict the Burden of X4 Quasispecies Detected by Pyrosequencing. Paper presented at 3th ICAR – Italian Conference on AIDS and Retroviruses, Firenze, Italia. Dettagli
  79. Salpini, R., Svicher, V., Cento, V., Gori, C., Bertoli, A., Scopelliti, F., et al. (2011). Characterization of drug-resistance mutations in HBV D-genotype chronically infected patients, naïve to antiviral drugs. ANTIVIRAL RESEARCH, 92(2), 382-385. Dettagli
  80. Santoro, M., Armenia, D., Fabeni, L., Santoro, M., Gori, C., Forbici, F., et al. (2011). The Lowest X4 Geno2Pheno-False Positive Rate Is Associated with Greater CD4-Depletion. Paper presented at 3th ICAR – Italian Conference on AIDS and Retroviruses, Firenze, Italia. Dettagli
  81. Sarrecchia, C., Svicher, V., Volpi, A., Salpini, R., Ceccarelli, L., Sordillo, P., et al. (2011). Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance. INFECTION. Dettagli
  82. Surdo, M., Balestra, E., Saccomandi, P., Di Santo, F., Svicher, V., Alteri, C., et al. (2011). Dual mixed (but not X4) tropic-HIV-1 isolates can replicate in human primary macrophages and are inhibited by CCR5- inhibitors. Paper presented at 3th ICAR – Italian Conference on AIDS and Retroviruses, Firenze, Italia. Dettagli
  83. Svicher, V., Alteri, C., Artese, A., Zhang, J., Costa, G., Mercurio, F., et al. (2011). Identification and structural characterization of novel genetic elements in the HIV-1 V3 loop regulating coreceptor usage. ANTIVIRAL THERAPY, 16(7), 1035-1045. Dettagli
  84. Svicher, V., Cento, V., Bernassola, M., Neumann Fraune, M., Salpini, R., Longo, R., et al. (2011). Specific HBSAG Genetic- Determinants are associated with occult HBV-infection in vivo and HBSAG detection. Paper presented at 46th Annual meeting of the European Association for the study of the liver, Berlin, Germany. Dettagli
  85. Svicher, V., Cento, V., Bernassola, M., Neumann-Fraune, M., Chen, M., Salpini, R., et al. (2011). Specific HbsAg genetic determinants are associated with occult HBV infection in vivo and HbsAg detection. Paper presented at International Workshop on HIV & Hepatitis virus Drug Resistance and curative strategies, Los Cabos (Mexico). Dettagli
  86. Svicher, V., Cento, V., Salpini, R., Mercurio, F., Fraune, M., Beggel, B., et al. (2011). Role of hepatitis B virus genetic barrier in drug-resistance and immune-escape development. DIGESTIVE AND LIVER DISEASE, 43(12), 975-983. Dettagli
  87. Svicher, V., Chen, M., Alteri, C., Costa, G., Dimonte, S., Chang, L., et al. (2011). Key genetic elements in HIV-1 gp120 V1,V2 and C4 domains tightly and differentially modulate gp120 interaction with the CCR5 and CXCR4 N terminus and HIV-1 antigenetic Potential. Dettagli
  88. Svicher, V., Chen, M., Alteri, C., Costa, G., Dimonte, S., Chang, L., et al. (2011). Key genetic elements in HIV-1 gp120 V1,V2 and C4 domains tightly and differentially modulate gp120 interaction with the CCR5 and CXCR4 N terminus and HIV-1 antigenetic Potential. Paper presented at International on HIV & Hepatitis virus Drug Resistance Workshop & curative strategies, Los Cabos, Mexico. Dettagli
  89. Svicher, V., Alteri, C., Gori, C., Salpini, R., Marcuccilli, F., Bertoli, A., et al. (2010). Lamivudine-resistance mutations can be selected even at very low levels of hepatitis B viraemia. DIGESTIVE AND LIVER DISEASE, 42(12), 902-907. Dettagli
  90. Svicher, V., Alteri, C., Artese, A., Forbici, F., Santoro, M.M., Schols, D., et al. (2010). Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimens. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 55(3), 336-344. Dettagli
  91. Ceccherini-Silberstein, F., Malet, I., Fabeni, L., Dimonte, S., Svicher, V., D'Arrigo, R., et al. (2010). Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 65(11), 2305-2318. Dettagli
  92. Svicher V, Alteri C, Artese A, Forbici F, Santoro MM, Schols D, et al. (2010). Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimens. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 55(3), 336-344. Dettagli
  93. Svicher, V., D'Arrigo, R., Alteri, C., Andreoni, M., Angarano, G., Antinori, A., et al. (2010). Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group. NEW MICROBIOLOGICA, 33(3), 195-206. Dettagli
  94. Svicher, V., Alteri, C., D'Arrigo, R., Laganà, A., Trignetti, M., Lo Caputo, S., et al. (2009). Treatment with the fusion inhibitor enfuvirtide influences the appearance of mutations in the human immunodeficiency virus type 1 regulatory protein rev. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 53(7), 2816-2823. Dettagli
  95. Svicher, V., Gori, C., Trignetti, M., Visca, M., Micheli, V., Bernassola, M., et al. (2009). The profile of mutational clusters associated with lamivudine resistance can be constrained by HBV genotypes. JOURNAL OF HEPATOLOGY, 50(3), 461-470. Dettagli
  96. Trignetti, M., Sing, T., Svicher, V., Santoro, M., Forbici, F., D'arrigo, R., et al. (2009). Dynamics of NRTI resistance mutations during therapy interruption. AIDS RESEARCH AND HUMAN RETROVIRUSES, 25(1), 57-64. Dettagli
  97. Alcaro, S., Artese, A., Ceccherini-Silberstein, F., Ortuso, F., Perno, C.F., Sing, T., et al. (2009). Molecular dynamics and free energy studies on the wild-type and mutated hiv-1 protease complexed with four approved drugs: Mechanism of binding and drug resistance. JOURNAL OF CHEMICAL INFORMATION AND MODELING, 49(7), 1751-1761. Dettagli
  98. Alteri, C., Svicher, V., Gori, C., D'Arrigo, R., Ciccozzi, M., Ceccherini-Silberstein, F., et al. (2009). Characterization of the patterns of drug-resistance mutations in newly diagnosed HIV-1 infected patients naive to the antiretroviral drugs. BMC INFECTIOUS DISEASES, 9, 111. Dettagli
  99. Svicher, V., Aquaro, S., D'Arrigo, R., Artese, A., Dimonte, S., Alcaro, S., et al. (2008). Specific enfuvirtide-associated mutational pathways in HIV-1 Gp41 are significantly correlated with an increase in CD4(+) cell count, despite virological failure. THE JOURNAL OF INFECTIOUS DISEASES, 197(10), 1408-1418. Dettagli
  100. Aquaro, S., Svicher, V., Ronga, L., Perno, C., & Pollicita, M. (2008). HIV-1-associated dementia during HAART therapy. RECENT PATENTS ON CNS DRUG DISCOVERY, 3(1), 23-33. Dettagli
  101. Ceccherini-Silberstein, F., Svicher, V., Sing, T., Artese, A., Santoro, M., Forbici, F., et al. (2007). Characterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors. JOURNAL OF VIROLOGY, 81(20), 11507-11519. Dettagli
  102. Perno, C.F., Svicher, V., Ceccherini-Silberstein, F., & Ciotti, M. (2007). Papillomavirus and cervical cancer: Epidemiology, genetics and prevention [Il papillomavirus umano e il cancro della cervice uterina: Epidemiologia, basi genetiche e prevenzione]. ITALIAN JOURNAL OF GYNAECOLOGY & OBSTETRICS, 19(4), 198-207. Dettagli
  103. Aquaro, S., D'Arrigo, R., Svicher, V., Perri, G., Caputo, S., Visco-Comandini, U., et al. (2006). Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 58(4), 714-722. Dettagli
  104. Svicher, V., Sing, T., Santoro, M., Forbici, F., Rodríguez-Barrios, F., Bertoli, A., et al. (2006). Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors. JOURNAL OF VIROLOGY, 80(14), 7186-7198. Dettagli
  105. Santoro, M., Svicher, V., Gori, C., Zaccarelli, M., Tozzi, V., Forbici, F., et al. (2006). Temporal characterization of drug resistance associated mutations in HIV-1 protease and reverse transcriptase in patients failing antiretroviral therapy. NEW MICROBIOLOGICA, 29(2), 89-100. Dettagli
  106. Aquaro, S., Svicher, V., & Perno, C.F. (2006). Does residual virus replication during successful HAART lead to HIV-1 genetic evolution?. JOURNAL OF HIV THERAPY, 11(4), 84-88. Dettagli
  107. Aquaro, S., Svicher, V., Schols, D., Pollicita, M., Antinori, A., Balzarini, J., et al. (2006). Mechanisms underlying activity of antiretroviral drugs in HIV-1-infected macrophages: New therapeutic strategies. JOURNAL OF LEUKOCYTE BIOLOGY, 80(5), 1103-1110. Dettagli
  108. Perno, C.F., Svicher, V., & Ceccherini-Silberstein, F. (2006). Novel drug resistance mutations in HIV: Recognition and clinical relevance. AIDS REVIEWS, 8(4), 179-190. Dettagli
  109. Perno, C.F., Svicher, V., Schols, D., Pollicita, M., Balzarini, J., & Aquaro, S. (2006). Therapeutic strategies towards HIV-1 infection in macrophages. ANTIVIRAL RESEARCH, 71(2-3 SPEC. ISS.), 293-300. Dettagli
  110. Bellocchi, M.C., Forbici, F., Palombi, L., Gori, C., Coelho, E., Svicher, V., et al. (2005). Subtype analysis and mutations to antiviral drugs in HIV-1-infected patients from Mozambique before initiation of antiretroviral therapy: Results from the DREAM programme. JOURNAL OF MEDICAL VIROLOGY, 76(4), 452-458. Dettagli
  111. Ceccherini-Silberstein, F., Gago, F., Santoro, M., Gori, C., Svicher, V., Rodríguez-Barrios, F., et al. (2005). High sequence conservation of human immunodeficiency virus type 1 reverse transcriptase under drug pressure despite the continuous appearance of mutations. JOURNAL OF VIROLOGY, 79(16), 10718-10729. Dettagli
  112. Aquaro, S., Svicher, V., Ceccherini-Silberstein, F., Cenci, A., Marcuccilli, F., Giannella, S., et al. (2005). Limited development and progression of resistance of HIV-1 to the nucleoside analogue reverse transcriptase inhibitor lamivudine in human primary macrophages. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 55(6), 872-878. Dettagli
  113. Aquaro, S., Svicher, V., Ceccherini-Silberstein, F., Cenci, A., Marcuccilli, F., Giannella, S., et al. (2005). Limited development and progression of resistance of HIV-1 to the nucleoside analogue reverse transcriptase inhibitor lamivudine in human primary macrophages. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 55(6), 872-878. Dettagli
  114. Sing, T., Svicher, V., Beerenwinkel, N., Ceccherini-Silberstein, F., Daumer, M., Kaiser, R., et al. (2005). Characterization of novel HIV drug resistance mutations using clustering, multidimensional scaling and SVM-based feature ranking. In Knowledge discovery in databases: PKDD 2005: 9th European conference on principles and practice of knowledge discovery in databases: Porto, Portugal, October 3-7, 2005: proceedings (pp.285-296). Springer. Dettagli
  115. Svicher, V., Ceccherini Silberstein, F., Erba, F., Santoro, M.G., Gori, C., Bellocchi, M.C., et al. (2005). Novel human immunodeficiency virus type 1 protease mutations potentially involved in resistance to protease inhibitors. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 49(5), 2015-2025. Dettagli
  116. Santoro, M., Ceccherini-Silberstein, F., Gori, C., Svicher, V., Forbici, F., Bellocchi, M., et al. (2004). Temporal change in the use of genotypic resistance testing over the years 1999--2003. NEW MICROBIOLOGICA, 27(2 Suppl 1), 141-144. Dettagli